As per Intent Market Research, the Biobank Market was valued at USD 71.0 billion in 2023 and will surpass USD 128.6 billion by 2030; growing at a CAGR of 8.9% during 2024 - 2030.
The global biobank market is poised for robust growth, driven by advancements in biotechnology, genomics, and personalized medicine. Biobanks play a pivotal role in disease research, drug discovery, and regenerative medicine by storing high-quality biological samples. As governments and private organizations increase their investments in healthcare and R&D, the demand for efficient biobanking solutions continues to rise. The market's expansion is further fueled by technological innovations in cryogenic storage and data integration, alongside growing awareness of the importance of biobanks in tackling global health challenges.
Cryogenic Storage Systems Lead Due to Advanced Preservation Capabilities
Cryogenic storage systems are the backbone of modern biobanks, offering unparalleled capabilities for long-term preservation of biological samples. This subsegment, encompassing refrigerators, ice machines, and freezers, holds the largest share in the equipment segment. Its dominance stems from the critical need for ultra-low temperature storage to maintain sample integrity, particularly for stem cells, DNA, and tissue specimens.
The market's growth is propelled by advancements in energy-efficient freezers and automated storage systems, which improve operational efficiency and sustainability. For instance, innovative cryogenic freezers equipped with AI-based monitoring systems are becoming standard, ensuring real-time temperature control and data logging. This technology is particularly crucial in large-scale biorepositories supporting global research initiatives.
DNA/RNA Biobanking Is Fastest Growing With Rising Genomics Research
Among sample types, DNA/RNA biobanking is experiencing the fastest growth, driven by the burgeoning field of genomics and personalized medicine. As researchers strive to unravel genetic markers for complex diseases, the demand for high-quality DNA and RNA samples has surged. This subsegment supports a wide array of applications, including cancer research, rare disease studies, and drug development.
Biobanks specializing in nucleic acid storage have adopted advanced preservation techniques, such as cryopreservation and lyophilization, to ensure sample stability. Strategic collaborations between biobanks and genomics companies further accelerate the segment's growth, underscoring its critical role in modern healthcare innovations.
Regenerative Medicine Dominates With Cutting-Edge Applications
Regenerative medicine is the largest application segment within the biobank market, reflecting the transformative potential of cell and tissue therapies. Biobanks serve as a vital resource in this domain by providing access to stem cells, tissues, and other biomaterials required for groundbreaking treatments. The field's rapid expansion is attributed to its ability to address unmet medical needs, including organ regeneration and chronic disease management.
Key advancements include the integration of 3D bioprinting and cell engineering technologies, which rely heavily on biobank resources. Furthermore, regulatory support and funding for regenerative medicine research have bolstered the segment’s prominence, making it a cornerstone of the biobank market.
Asia-Pacific Emerges as Fastest Growing Region With Strategic Investments
Asia-Pacific is the fastest-growing region in the biobank market, fueled by increasing investments in biotechnology and healthcare infrastructure. Countries such as China, India, and Japan are spearheading growth with robust government support for genomic research and biobanking initiatives. For example, China’s National Genomics Data Center and India’s Department of Biotechnology are key players driving regional progress.
The region's growth is further supported by the rising prevalence of chronic diseases and growing interest in personalized medicine. Collaboration between international organizations and local biobanks has also enhanced the availability of high-quality samples, positioning Asia-Pacific as a global hub for biobanking innovation.
Competitive Landscape Led by Technology and Collaboration
The biobank market is moderately competitive, with key players like Thermo Fisher Scientific, Qiagen, and BioLife Solutions driving innovation through strategic collaborations and product development. Companies focus on integrating cutting-edge technologies, such as automated storage systems and AI-driven monitoring tools, to enhance operational efficiency and expand their offerings.
Recent mergers, acquisitions, and partnerships have shaped the competitive landscape, highlighting the industry's dynamic nature. For example, BioLife Solutions' acquisition of a cryogenic equipment manufacturer underscores the trend of vertical integration. As biobanks increasingly partner with academic and clinical institutions, the market is expected to see further consolidation, fostering an ecosystem of innovation and growth.
By leveraging advancements in technology and fostering collaborations, the biobank market is poised to remain a critical enabler of global healthcare and research progress.
Recent Developments:
- Thermo Fisher Scientific launched a next-generation biobanking solution to enhance cryogenic storage efficiency.
- Hamilton Company announced its acquisition of a new facility to expand its storage solutions portfolio.
- BioLife Solutions acquired a key stake in a cryogenic equipment manufacturer to strengthen its market presence.
- STEMCELL Technologies received regulatory clearance for its new preservation medium designed for stem cell samples.
- Qiagen partnered with leading research institutes to provide integrated biobanking solutions for genomic studies.
List of Leading Companies:
- Thermo Fisher Scientific
- Qiagen
- Hamilton Company
- Tecan Trading AG
- Brooks Life Sciences
- BioLifeSolutions Inc.
- STEMCELL Technologies
- VWR International
- Promega Corporation
- BioIVT
- LabVantage Solutions
- Beckman Coulter
- Panasonic Healthcare Holdings
- BD Biosciences
- Eppendorf AG
Report Scope:
Report Features |
Description |
Market Size (2023) |
USD 71.0 Billion |
Forecasted Value (2030) |
USD 128.6 Billion |
CAGR (2024 – 2030) |
8.9% |
Base Year for Estimation |
2023 |
Historic Year |
2022 |
Forecast Period |
2024 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Biobank Market by Equipment (Cryogenic Storage Systems, Alarm Monitoring Systems), by Sample Type (Human Tissue Biobanking, Stem Cell Biobanking, Cord Biobanking, DNA/RNA Biobanking), by Application (Regenerative Medicine, Drug Discovery, Disease Research) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
Thermo Fisher Scientific, Qiagen, Hamilton Company, Tecan Trading AG, Brooks Life Sciences, BioLifeSolutions Inc., STEMCELL Technologies, VWR International, Promega Corporation, BioIVT, LabVantage Solutions, Beckman Coulter, Panasonic Healthcare Holdings, BD Biosciences, Eppendorf AG |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Biobank Market, by Equipment (Market Size & Forecast: USD Million, 2022 – 2030) |
4.1. Cryogenic Storage Systems |
4.2. Alarm Monitoring Systems |
4.3. Other Equipment |
5. Biobank Market, by Sample Type (Market Size & Forecast: USD Million, 2022 – 2030) |
5.1. Human Tissue Biobanking |
5.2. Stem Cell Biobanking |
5.3. Cord Biobanking |
5.4. DNA/RNA Biobanking |
5.5. Other Services |
6. Biobank Market, by Application (Market Size & Forecast: USD Million, 2022 – 2030) |
6.1. Regenerative Medicine |
6.2. Drug Discovery |
6.3. Disease Research |
7. Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030) |
7.1. Regional Overview |
7.2. North America |
7.2.1. Regional Trends & Growth Drivers |
7.2.2. Barriers & Challenges |
7.2.3. Opportunities |
7.2.4. Factor Impact Analysis |
7.2.5. Technology Trends |
7.2.6. North America Biobank Market, by Equipment |
7.2.7. North America Biobank Market, by Sample Type |
7.2.8. North America Biobank Market, by Application |
7.2.9. By Country |
7.2.9.1. US |
7.2.9.1.1. US Biobank Market, by Equipment |
7.2.9.1.2. US Biobank Market, by Sample Type |
7.2.9.1.3. US Biobank Market, by Application |
7.2.9.2. Canada |
7.2.9.3. Mexico |
*Similar segmentation will be provided for each region and country |
7.3. Europe |
7.4. Asia-Pacific |
7.5. Latin America |
7.6. Middle East & Africa |
8. Competitive Landscape |
8.1. Overview of the Key Players |
8.2. Competitive Ecosystem |
8.2.1. Level of Fragmentation |
8.2.2. Market Consolidation |
8.2.3. Product Innovation |
8.3. Company Share Analysis |
8.4. Company Benchmarking Matrix |
8.4.1. Strategic Overview |
8.4.2. Product Innovations |
8.5. Start-up Ecosystem |
8.6. Strategic Competitive Insights/ Customer Imperatives |
8.7. ESG Matrix/ Sustainability Matrix |
8.8. Manufacturing Network |
8.8.1. Locations |
8.8.2. Supply Chain and Logistics |
8.8.3. Product Flexibility/Customization |
8.8.4. Digital Transformation and Connectivity |
8.8.5. Environmental and Regulatory Compliance |
8.9. Technology Readiness Level Matrix |
8.10. Technology Maturity Curve |
8.11. Buying Criteria |
9. Company Profiles |
9.1. Thermo Fisher Scientific |
9.1.1. Company Overview |
9.1.2. Company Financials |
9.1.3. Product/Service Portfolio |
9.1.4. Recent Developments |
9.1.5. IMR Analysis |
*Similar information will be provided for other companies |
9.2. Qiagen |
9.3. Hamilton Company |
9.4. Tecan Trading AG |
9.5. Brooks Life Sciences |
9.6. BioLifeSolutions Inc. |
9.7. STEMCELL Technologies |
9.8. VWR International |
9.9. Promega Corporation |
9.10. BioIVT |
9.11. LabVantage Solutions |
9.12. Beckman Coulter |
9.13. Panasonic Healthcare Holdings |
9.14. BD Biosciences |
9.15. Eppendorf AG |
10. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Biobank Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Biobank Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the Biobank ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Biobank Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA